The assay also distinguishes patients with AD from age-matched healthy controls, which is in agreement with mass spectrometry data on p-tau T217.24 Low levels of p-tau T217 in healthy controls could be caused by rapid degradation (or dephosphorylation) of tau species phosphorylated at this particular position. This evidence concerns the gene MAPT and Alzheimer disease.